GSK3B and breast cancer: A recent study further reported that EGF could stabilize PD-L1 via GSK3beta inactivation in basal-like breast cancer and inhibiting EGF signalling by gefitinib destabilized PD-L1 and enhanced anti-tumour efficacy of PD-1 blockade in mouse models [28].